ArticleFrontiers in behavioral neuroscience2026
Stable rat models in constipation with depression and anxiety: evaluation and validation.
Article in Frontiers in behavioral neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The study aimed to establish a model of functional constipation (FC) with anxiety and depression in rats using the compound diphenoxylate combined with chronic unpredictable mild stress (CUMS). It further investigated constipation and behavioral indicators in different groups of various compounds of diphenoxylate with CUMS durations to determine the optimal time frame for successful model establishment. Method: Thirty-two female rats were randomly assigned to control, FC before CUMS, FC after CUMS, and FC throughout CUMS groups. Control: Same amount of regular saline solution, FC before CUMS: Compound diphenoxylate 15 mg/kg 2 weeks + CUMS 5 weeks, FC after CUMS: CUMS 5 weeks + Compound diphenoxylate 15 mg/kg 2 weeks, FC throughout CUMS: CUMS 5 weeks with compound diphenoxylate 10 mg/kg for 4 weeks. After model establishment, constipation and behavioral indicators were detected. HE staining was used to observe pathological changes in the brain and colon tissue, while AB-PAS was used to observe goblet cells in the colon tissue, and Nissl staining was used to observe neuron cells in the hippocampus. The protein expression of BDNF and Bax in the hippocampus and PGP9.5 and iNOS in the colon was detected by WB. Results: In the FC throughout group, synaptic ultrastructure significantly decreased, aligning with pathological changes, indicators of FC with anxiety and depression. The protein expression levels of BDNF and PGP9.5 were markedly decreased, and the levels of Bax and iNOS were elevated. This study provided a reliable reference for determining the optimal establishment way of FC with anxiety and depression models and for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.